

Special Issue

T Cell Responses in SARS-CoV-2

Message from the Guest Editors

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is affecting the world's population in manifold ways, and we are still searching for solutions in order to reach the stage of controlled endemicity. So far, research and vaccine development has largely focused on spike glycoprotein-specific antibody induction and stability, which is critical to avoid infection and limit the spread of SARS-CoV-2. However, increasing global immunity driving the evolution of escape mutations is increasing the importance of a broad, robust T-cell memory-based immunity. The development of second-generation vaccines will require an extensive knowledge of T-cell responses, including type and conservation of T-cell epitopes, pre-existing immunity as well as induction, compartmentalization, stability, and phenotype of overall T cell responses.

Guest Editors

Dr. Kilian Schober

Mikrobiologisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Dr. Lucie Loyal

1. Si-M / "Der Simulierte Mensch" a Science Framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany

2. Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin (BCRT), Germany

Deadline for manuscript submissions

closed (31 December 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/107147

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).